创新药ETF国泰(517110)利润分配表
| |
2025-12-31 |
2025-06-30 |
2024-12-31 |
2024-06-30 |
| 收入 |
71,029,758.39 |
63,776,860.02 |
-28,281,116.87 |
-50,504,830.04 |
| 利息合计 |
20,345.40 |
8,541.57 |
17,391.03 |
7,032.11 |
| 其中:存款利息收入 |
20,345.40 |
8,541.57 |
17,391.03 |
7,032.11 |
| 债券利息收入 |
- |
- |
- |
- |
| 资产支持证券利息收入 |
- |
- |
- |
- |
| 买入返售金融资产收入 |
- |
- |
- |
- |
| 投资收益合计 |
22,462,908.12 |
3,961,703.93 |
-17,513,998.22 |
-11,503,382.88 |
| 其中:股票投资收益 |
19,726,686.70 |
2,376,274.04 |
-19,606,429.16 |
-12,780,173.92 |
| 基金投资收益 |
- |
- |
- |
- |
| 债券投资收益 |
- |
- |
- |
- |
| 资产支持证券投资收益 |
- |
- |
- |
- |
| 衍生工具收益 |
- |
- |
- |
- |
| 股利收益 |
2,736,221.42 |
1,585,429.89 |
2,092,430.94 |
1,276,791.04 |
| 基金分红收益收益 |
- |
- |
- |
- |
| 公允价值变动收益 |
47,396,687.17 |
59,622,041.57 |
-11,122,852.64 |
-39,137,663.28 |
| 其他收入 |
1,149,817.70 |
184,572.95 |
338,342.96 |
129,184.01 |
| 费用 |
2,147,717.10 |
870,034.08 |
1,157,043.72 |
528,203.72 |
| 管理人报酬 |
1,642,302.14 |
654,648.50 |
832,078.60 |
369,764.63 |
| 基金托管费 |
328,460.41 |
130,929.71 |
166,415.73 |
73,952.99 |
| 销售服务费 |
- |
- |
- |
- |
| 交易费用 |
- |
- |
- |
- |
| 利息支出 |
- |
- |
- |
- |
| 其中:卖出回购金融资产支出 |
- |
- |
- |
- |
| 其他费用 |
176,954.55 |
84,455.87 |
158,549.39 |
84,486.10 |
| 利润总额 |
68,882,041.29 |
62,906,825.94 |
-29,438,160.59 |
-51,033,033.76 |
欢迎访问证券之星!请点此与我们联系 版权所有: Copyright © 1996-年